WG
MRKR icon

Winton Group’s Marker Therapeutics MRKR Stock Holding History

Winton Group’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,031
Closed -$53K – 1698
2019
Q3 		$53K Sell
1,031
-344
-25% -$20.3K ﹤0.01% 1496
2019
Q2 		$109K Sell
1,375
-11
-0.8% -$653 ﹤0.01% 1076
2019
Q1 		$91K Buy
+1,386
New +$80.9K ﹤0.01% 1034

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Winton Group's MRKR Position: Q4 2019 in Review

Winton Group sold out of Marker Therapeutics (MRKR) in Q4 2019, closing a stake of 1,031 shares — an estimated $53K sold.

Winton Group first reported a position in MRKR in Q1 2019 and held it in 3 quarters. The position peaked at $109K in Q2 2019. 65 funds tracked by Wall St. Rank hold MRKR as of Q4 2019.

  • Winton Group reported no remaining Marker Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Winton Group sold 1,031 Marker Therapeutics shares in Q4 2019, an estimated $53K.
  • Winton Group first reported a position in Marker Therapeutics in Q1 2019 and held it in 3 quarters.
  • Winton Group's Marker Therapeutics position peaked at $109K in Q2 2019.
  • 65 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2019.

Based on Winton Group's 13F filing for Q4 2019, filed 13 Feb 2020.